- Home
- PTLO vs MLYS Comparison
PTLO vs MLYS Comparison
Compare PTLO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- MLYS
- Stock Information
- Founded
- PTLO 1963
- MLYS 2019
- Country
- PTLO United States
- MLYS United States
- Employees
- PTLO N/A
- MLYS N/A
- Industry
- PTLO Restaurants
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- MLYS Health Care
- Exchange
- PTLO Nasdaq
- MLYS Nasdaq
- Market Cap
- PTLO 799.0M
- MLYS 893.0M
- IPO Year
- PTLO 2021
- MLYS 2023
- Fundamental
- Price
- PTLO $10.73
- MLYS $12.12
- Analyst Decision
- PTLO Buy
- MLYS Strong Buy
- Analyst Count
- PTLO 7
- MLYS 3
- Target Price
- PTLO $14.29
- MLYS $33.00
- AVG Volume (30 Days)
- PTLO 1.3M
- MLYS 2.3M
- Earning Date
- PTLO 05-06-2025
- MLYS 05-08-2025
- Dividend Yield
- PTLO N/A
- MLYS N/A
- EPS Growth
- PTLO 43.75
- MLYS N/A
- EPS
- PTLO 0.46
- MLYS N/A
- Revenue
- PTLO $710,554,000.00
- MLYS N/A
- Revenue This Year
- PTLO $13.64
- MLYS N/A
- Revenue Next Year
- PTLO $13.84
- MLYS N/A
- P/E Ratio
- PTLO $24.65
- MLYS N/A
- Revenue Growth
- PTLO 4.51
- MLYS N/A
- 52 Week Low
- PTLO $8.38
- MLYS $8.24
- 52 Week High
- PTLO $15.78
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- PTLO 32.39
- MLYS 46.14
- Support Level
- PTLO $11.55
- MLYS $13.00
- Resistance Level
- PTLO $12.46
- MLYS $17.17
- Average True Range (ATR)
- PTLO 0.54
- MLYS 1.44
- MACD
- PTLO -0.13
- MLYS -0.46
- Stochastic Oscillator
- PTLO 4.47
- MLYS 2.19
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.